TABLE 1

Demographic and Other Information on Study Participants

CharacteristicMD2Me (N = 40)Control (N = 41)
Age, median (minimum, maximum), y17 (12, 20)17 (12, 19)
Gender (male:female), n 17:2320:21
Race/ethnicity, n
 White1611
 Black44
 Hispanic1822
 American Indian/Alaskan10
 Other14
Disease category, n
 IBD
  CD1112
  UC65
 CF67
 T1D1717
Disease duration, median (IQR), y4 (3–9)6 (2–10)
Disease status, median (IQR)
 UC
  PUCAI3 (0–21)0 (0–10)
 CD
  PCDAI5 (5–10)10 (1–20)
 CF
  CFCS19 (17–24)18 (14–25)
 FEV1%87 (69–94)81 (72–98)
 T1D
  DQoL47 (44–49)45 (35–52)
  Glycohemoglobin, %8.2 (7–9.2)8.6 (7.9–9.5)
Karnofsky Performance Scale, median (IQR)90 (90–100)90 (80–100)
TOFHLA, median (minimum, maximum)82 (74, 88)81 (70, 89)
PedsQL, median (IQR)81 (70–91)77 (64–88)
  • CD, Crohn disease; CFCS, Cystic Fibrosis Clinical Score; DQoL, Diabetes Quality of Life Brief Clinical Inventory; FEV1%, baseline predicted forced expiratory volume in 1 second by percentage; IBD, inflammatory bowel disease; IQR, interquartile range; PCDAI, Pediatric Crohn’s Disease Activity Index; PedsQL, Pediatric Quality of Life Scale; PUCAI, Pediatric Ulcerative Colitis Activity Index; TOFHLA, Test of Functional Health Literacy in Adults; UC, ulcerative colitis.